Early dual treatment helps late-diagnosed PAH patients catch up

Robyn Kalda
Jul 21, 2025
1 min read

Early use of dual therapy helps newly-diagnosed pulmonary arterial hypertension patients do as well as patients six months past diagnosis.

Newly-diagnosed patients' health is often worse than patients who have been treated for six months or more. However, US registry data showed that newly-diagnosed patients given macitentan and tadalafil had, after a year, similar survival and hospitalization rates to prevalent patients. Starting dual therapy soon after diagnosis may have some benefit.

Read the Advances in Therapy article

Recent Posts

Exercise is safe and effective for PH patients

Researchers conducted a meta-analysis, looking at 13 studies with about 700 participants in total with pulmonary hypertension (PH). They found that exercise improved 6-minute walk distance and was con

In CTEPH, antioxidant enzyme PRDX2 reduces inflammation

A study found that chronic thromboembolic pulmonary hypertensio (CTEPH) patients had significantly more of an antioxidant enzyme (peroxiredoxin 2, or PRDX2) in their bloodstream compared to healthy pa

Early diagnosis and treatment of PAH improve survival

This study examined the causes of delayed diagnosis (diagnosis after approximately 22 months) of pulmonary arterial hypertension (PAH) and whether an earlier diagnosis (within six months) leads to bet

Comments